Olfactory testing sits at the center of this dementia and brain health question.

Olfactory testing has emerged as a promising, non-invasive screening tool for identifying early-stage Alzheimer’s disease and cognitive decline. Rather than relying on expensive brain imaging or invasive procedures, researchers are finding that simple smell tests—measuring a person’s ability to identify odors, distinguish between them, and remember scents—can reveal neurological changes years before memory problems become apparent. Recent developments like the AROMHA Brain Health Test, developed by researchers at Massachusetts General Hospital, now allow people to complete olfactory assessments from home, making this screening method accessible to broader populations who might not otherwise undergo early detection testing.

The underlying science is solid: the olfactory system connects directly to brain regions that Alzheimer’s attacks first. The primary olfactory cortex, along with interconnected structures like the hippocampus and entorhinal cortex, shows some of the earliest signs of Alzheimer’s pathology. This means smell loss often precedes any noticeable memory issues by several years, appearing during the subjective cognitive decline stage—before a person even meets criteria for mild cognitive impairment. This article explores how olfactory testing works, what clinical evidence supports it, how it compares to current screening methods, and what limitations practitioners and patients should understand.

Why Smell Loss Signals Early Alzheimer’s Disease
Olfactory Testing Methods: From Simple Screening to Digital Assessment
Clinical Evidence Supporting Olfactory Testing for Early Detection
How Olfactory Testing Compares to Current Alzheimer’s Screening Approaches
What Olfactory Testing Can and Cannot Tell Us
Bringing Olfactory Testing into Clinical Practice
The Future of Smell-Based Alzheimer’s Screening
Conclusion

Why Smell Loss Signals Early Alzheimer’s Disease

The connection between smell and Alzheimer’s disease isn’t coincidental—it’s rooted in the brain’s anatomy. The olfactory bulb, which processes smell, sits just above the nasal cavity and connects directly to multiple brain regions implicated in Alzheimer’s pathology. From there, olfactory signals reach the primary olfactory cortex, which then connects to the hippocampus (crucial for memory), the entorhinal cortex (involved in navigation and memory), and the amygdala (linked to emotion and memory processing). When Alzheimer’s pathology—primarily amyloid-beta plaques and tau tangles—begins accumulating in the brain, these interconnected olfactory regions are often among the first affected.

Research published in Nature Scientific Reports and reviewed across multiple institutions shows that olfactory impairment can appear years before cognitive symptoms become severe enough to interfere with daily life. This makes smell testing valuable as a potential biomarker during the subjective cognitive decline stage, the earliest detectable phase of cognitive change. A person with olfactory impairment during this stage may report feeling mentally sharp and perform normally on standard cognitive tests, yet they’re showing measurable neurological change. For families with a history of Alzheimer’s or individuals over 55 who want to monitor their cognitive health, this early signal offers time for intervention, lifestyle modifications, and clinical monitoring before more advanced decline occurs.

Why Smell Loss Signals Early Alzheimer's Disease

Olfactory Testing Methods: From Simple Screening to Digital Assessment

The simplest and most well-validated olfactory test is the Sniffin’ Sticks Test, a straightforward pen-based assessment where a person identifies odors, discriminates between similar smells, and recalls scents from earlier in the test. Clinicians can administer this test in primary care settings with minimal equipment or training, making it practical for routine health screenings. The test takes just 15-20 minutes and provides a score that can be compared against normative data and tracked over time. More recently, the AROMHA Brain Health Test represents a technological evolution. Developed by Massachusetts General Hospital researchers, AROMHA is a digital remote tool that people can use at home, incorporating odor identification, discrimination, memory, and intensity assessments through a smartphone or computer interface.

This approach overcomes practical barriers—transportation, clinic scheduling, time constraints—that prevent many people from accessing early detection services. However, remote testing does introduce variables that in-clinic testing can control, such as ensuring odors are perceived at consistent intensity and that testing conditions are standardized. Results from studies published in Nature Scientific Reports (2025) show that AROMHA performs comparably to traditional in-person olfactory assessments while dramatically expanding who can participate in screening. Additionally, researchers at Duke University are exploring a different biomarker approach: nasal swabs that detect genetic differences associated with Alzheimer’s disease. Their work identified approximately 40 genes that differ between control groups and those with Alzheimer’s disease, published in March 2026. While nasal swab testing is still in earlier research phases, it represents a complementary approach—potentially combining genetic markers with behavioral olfactory assessment for even more robust early detection.

Clinical Evidence Supporting Olfactory Testing for Early Detection

The clinical evidence base for olfactory testing in Alzheimer’s screening has strengthened significantly in recent years. Studies show that when clinicians combine standard cognitive assessment with odor identification testing, diagnostic classification of Alzheimer’s disease and mild cognitive impairment improves substantially. Rather than relying solely on memory tests or general cognitive batteries—which can be insensitive to very early changes—adding olfactory assessment captures neurological changes that occur earlier in the disease process. One important advantage is that olfactory testing results are not confounded by education level, language barriers, or cultural differences in the way some cognitive tests are.

A person’s ability to smell is a relatively pure measure of olfactory system function, unaffected by how much schooling they’ve completed or which language they speak fluently. This makes olfactory testing particularly valuable in diverse populations and resource-limited settings where sophisticated neuropsychological testing may be unavailable. Research from Harvard documented that olfactory testing is “particularly valuable in resource-limited settings” precisely because it requires no expensive equipment, specialized training, or infrastructure. However, clinicians must remember that olfactory impairment can result from other causes—nasal polyps, chronic rhinosinusitis, smoking, COVID-19, and other neurological conditions—so smell loss is suggestive, not diagnostic on its own. Abnormal olfactory results should always prompt further evaluation rather than constitute a diagnosis.

Clinical Evidence Supporting Olfactory Testing for Early Detection

How Olfactory Testing Compares to Current Alzheimer’s Screening Approaches

Current Alzheimer’s screening relies on several approaches, each with distinct tradeoffs. Cognitive testing batteries administered by neuropsychologists are thorough but time-intensive and expensive; they can detect mild cognitive impairment but often show normal results in subjective cognitive decline. PET imaging reveals amyloid and tau burden in the brain but costs $3,000–$5,000 per scan, involves radiation exposure, and is not widely available. Blood biomarkers (phosphorylated tau, amyloid-beta ratios) are emerging as valuable tools and offer objective biological measures, but require lab infrastructure and can cost $300–$1,000 per panel.

Olfactory testing sits in a unique position: it costs significantly less than brain imaging or biomarker panels (typically $50–$200), requires no blood draws or radiation, can be administered by primary care staff or used at home, and detects neurological changes years before cognitive tests do. For someone concerned about cognitive health but not yet symptomatic enough to justify a $5,000 PET scan or extensive neuropsychological evaluation, olfactory testing offers a practical first step. The tradeoff is that olfactory impairment, while suggestive, is not perfectly specific to Alzheimer’s disease. A person with abnormal smell might have Parkinson’s disease, multiple sclerosis, or other conditions affecting olfaction. For this reason, olfactory testing works best as a screening tool that flags risk and prompts further evaluation rather than as a standalone diagnostic test.

What Olfactory Testing Can and Cannot Tell Us

It’s crucial to understand the boundaries of what olfactory testing can reveal. Olfactory impairment does predict increased risk for cognitive decline and Alzheimer’s disease, and it appears years earlier than memory problems. However, not everyone with smell loss will develop Alzheimer’s disease, and not everyone who eventually develops Alzheimer’s will show early olfactory impairment. Sensitivity and specificity vary depending on the test used, the population studied, and whether other biomarkers (such as amyloid or tau) are present. A normal smell test does not rule out Alzheimer’s; someone could have normal olfaction yet still have Alzheimer’s pathology building in their brain.

Environmental and health factors can confound results. Recent COVID-19 infection, for example, causes olfactory impairment that may persist for months; chronic smokers may have reduced smell sensation; people with untreated sleep apnea can experience smell loss. These factors don’t preclude olfactory testing from being useful, but they require clinicians to interpret results in context. Additionally, olfactory function naturally declines with age in healthy people—someone’s 80-year-old parent will almost certainly smell less well than their 50-year-old self, even without Alzheimer’s disease. Normative data and age-appropriate reference ranges help distinguish normal aging from pathological olfactory decline. The takeaway: olfactory testing is a valuable but imperfect tool best used as part of a comprehensive assessment rather than in isolation.

What Olfactory Testing Can and Cannot Tell Us

Bringing Olfactory Testing into Clinical Practice

Several factors make olfactory testing feasible for routine clinical use. The Sniffin’ Sticks Test requires minimal training; nurses or physician assistants can administer it during a regular office visit, and scores are straightforward to interpret. For primary care clinicians wanting to screen patients over 55 or those with cognitive concerns, olfactory testing can be incorporated into annual wellness visits with minimal disruption. Some practices have begun incorporating simple odor identification screening—even informal smell tests like asking patients to identify common odors—as part of cognitive assessment protocols.

The rise of remote testing through tools like AROMHA expands opportunities further. Patients can complete testing at home on their own schedule, results are automatically scored and compared to normative data, and results can be reviewed with their clinician at a telehealth visit. For rural patients, those with mobility limitations, or people managing multiple health conditions, home-based olfactory testing removes barriers to screening. However, implementing new screening tools requires education; many clinicians are not yet familiar with how to use olfactory testing results or how to counsel patients about what abnormal results mean. As more research and clinical guidance emerges, adoption is likely to increase, particularly as the evidence for olfactory testing’s prognostic value continues accumulating.

The Future of Smell-Based Alzheimer’s Screening

Research activity in olfactory dysfunction as a biomarker has accelerated substantially in 2025 and 2026. Multiple peer-reviewed studies are examining how olfactory impairment relates to functional connectivity changes in olfactory cortex, broader brain network alterations, and the progression from subjective cognitive decline to mild cognitive impairment. Frontiers in Neuroscience and other leading journals have published work documenting how smell-related brain networks change as Alzheimer’s pathology accumulates. This expanding evidence base strengthens the case for olfactory testing as a standard screening tool in cognitive assessment.

Additionally, emerging multimodal approaches are likely to enhance predictive power. Combining olfactory testing results with blood biomarkers (phosphorylated tau, amyloid), genetic risk factors (APOE4 status), and perhaps nasal swab genetic markers creates a more comprehensive early detection strategy. Rather than viewing olfactory testing as a replacement for existing screening methods, future practice will likely integrate it as one component of a multi-tool approach tailored to the individual patient. For someone with cognitive concerns or family history of Alzheimer’s, a simple smell test represents an accessible, non-invasive entry point to personalized cognitive risk assessment.

Conclusion

Olfactory testing represents a genuine advancement in non-invasive, accessible Alzheimer’s screening. The science is sound—smell impairment appears early in the disease process, reflects underlying brain pathology, and can be measured reliably with validated tools. For clinicians and patients seeking to identify cognitive risk before significant decline occurs, olfactory testing offers an inexpensive, practical, and evidence-supported approach that integrates easily into routine medical care.

The AROMHA test and emerging nasal swab biomarkers indicate that assessment methods will continue improving and expanding access. If you’re concerned about cognitive health—whether for yourself or a loved one—a conversation with your primary care clinician about olfactory screening is a reasonable starting point. A simple smell test takes minutes, costs far less than brain imaging, and could reveal early warning signs worth monitoring. Combined with other cognitive assessments, lifestyle modifications, and clinical follow-up, olfactory testing contributes meaningfully to early detection efforts that may offer more time for intervention and planning.